OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis
- Conditions
- Tuberculosis
- Interventions
- Drug: Optimized Background Regimen (OBR)
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2021-11-11
- Target Recruit Count
- 10
- Registration Number
- NCT01131351
- Locations
- 🇱🇹
Hospital for Tuberculosis and Lung Diseases, Siauliai, Lithuania
🇱🇻Infectology Center of Latvia - Clinic of Tuberculosis and Lung Diseases, Ogre, Latvia
🇱🇹National Tuberculosis and Infectious Diseases University Hospital, Vilnius, Lithuania
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2020-01-06
- Target Recruit Count
- 709
- Registration Number
- NCT01129882
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2021-12-22
- Target Recruit Count
- 173
- Registration Number
- NCT01123707
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
- Conditions
- Adolescent SchizophreniaChild or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2016-02-08
- Target Recruit Count
- 524
- Registration Number
- NCT01122927
- Locations
- 🇺🇦
Study Site, Vinnytsya, Ukraine
🇺🇦Study Site 2, Kharkiv, Ukraine
🇺🇦Study Site 1, Kharkiv, Ukraine
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2021-10-26
- Target Recruit Count
- 237
- Registration Number
- NCT01111552
- Locations
- 🇷🇴
Study Site 1, Bucuresti, Romania
🇷🇴Study Site 2, Bucuresti, Romania
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2021-12-21
- Target Recruit Count
- 137
- Registration Number
- NCT01111565
- Locations
- 🇿🇦
Study Site 1, Cape Town, South Africa
🇿🇦Study Site 2, Cape Town, South Africa
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2021-10-20
- Target Recruit Count
- 211
- Registration Number
- NCT01111539
- Locations
- 🇮🇳
Study Site 1, Ahmedabad, Gujarat, India
🇮🇳Study Site 2, Ahmedabad, Gujarat, India
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2023-02-02
- Target Recruit Count
- 740
- Registration Number
- NCT01074294
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2015-11-01
- Target Recruit Count
- 773
- Registration Number
- NCT01052077
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Southwestern Research, Beverly Hills, California, United States
🇺🇸California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2014-09-25
- Target Recruit Count
- 30
- Registration Number
- NCT01009840
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Maryland School of Medicine - Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States